Modifications of DNA by platinum complexes: Relation to resistance of tumors to platinum antitumor drugs

Drug Resistance Updates

Volumn 8, Issue 3, 2005, Pages 131-146

  Brabec, Viktor ^a   Kasparkova, Jana ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

Author keywords

Cisplatin; DNA; New platinum drugs; NF B; p53; Repair; Telomerase; Transplatin; Trinuclear platinum drugs

Indexed keywords

ANTINEOPLASTIC AGENT; BBR 3464; CARBOPLATIN; CISPLATIN; DISTAMYCIN A; FLUOROURACIL; FOLINIC ACID; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEDAPLATIN; OXALIPLATIN; PLATINUM; PLATINUM COMPLEX; PROTEIN P53; TRANSPLATIN; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CORRELATION ANALYSIS; DNA ADDUCT; DNA BINDING; DNA CONFORMATION; DNA DAMAGE; DNA MODIFICATION; DNA REPAIR; DRUG INACTIVATION; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MOLECULAR MECHANICS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TUMOR RESISTANCE;

EID: 24644443129     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2005.04.006     Document Type: Article

References (140)

1. S. Aebi, B. KurdiHaidar, R. Gordon, B. Cenni, H. Zheng, and D. Fink Loss of DNA mismatch repair in acquired resistance to cisplatin Cancer Res. 56 1996 3087 3090
2. R. Altaha, X.B. Liang, J.J. Yu, and E. Reed Excision repair cross complementing-group 1: gene expression and platinum resistance Int. J. Mol. Med. 14 2004 959 970
3. T. André, C. Boni, L. Mounedji-Boudiaf, M. Navarro, J. Tabernero, and T. Hickish Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N. Engl. J. Med. 350 2004 2343 2351
4. P.A. Andrews, S. Velury, S.C. Mann, and S.B. Howell cis-Diamminedichloro- platinum(II) accumulation in sensitive and resistant ovarian carcinoma cells Cancer Res. 48 1988 63 68
5. K.R. Barnes, A. Kutikov, and S.J. Lippard Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes Chem. Biol. 11 2004 557 564
6. C.G. Barry, C.S. Day, and U. Bierbach Duplex-promoted platination of adenine-N3 in the minor groove of DNA: challenging a longstanding bioinorganic paradigm J. Am. Chem. Soc. 127 2005 1160 1169
7. V. Beljanski, L.G. Marzilli, and P.W. Doetsch DNA damage-processing pathways involved in the eukaryotic cellular response to anticancer DNA cross-linking drugs Mol. Pharmacol. 65 2004 1496 1506
8. V. Bergoglio, Y. Canitrot, L. Hogarth, L. Minto, S.B. Howell, and C. Cazaux Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents Oncogene 20 2001 6181 6187
9. F.A. Blommaert, H.C.M. van Dijk-Knijnenburg, F.J. Dijt, L. Denengelse, R.A. Baan, and F. Berends Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells Biochemistry 34 1995 8474 8480
10. V. Brabec DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair Prog. Nucleic Acid Res. Mol. Biol. 71 2002 1 68
11. V. Brabec, and J. Kasparkova Molecular aspects of resistance to antitumor platinum drugs Drug Resist. Update 5 2002 147 161
12. V. Brabec, J. Kasparkova, O. Vrana, O. Novakova, J.W. Cox, and Y. Qu DNA modifications by a novel bifunctional trinuclear platinum Phase I anticancer agent Biochemistry 38 1999 6781 6790
13. V. Brabec, K. Neplechova, J. Kasparkova, and N. Farrell Steric control of DNA interstrand cross-link sites of trans platinum complexes: specificity can be dictated by planar nonleaving groups J. Biol. Inorg. Chem. 5 2000 364 368
14. 2] Nucleic Acids Res. 24 1996 336 341
15. M. Brendel, D. Bonatto, M. Strauss, L.F. Revers, C. Pungartnik, and J. Saffi Role of PSO genes in repair of DNA damage of Saccharomyces cerevisiae Mutat. Res. 544 2003 179 193
16. R.A. Britten, J. Peacock, and H.M. Warenius Collateral resistance to photon and neutron irradiation is associated with acquired cis-platinum resistance in human ovarian tumour cells Radiother. Oncol. 23 1992 170 175
17. G.J. Bubley, B.A. Teicher, G.K. Ogata, L.S. Sandoval, and T. Kusumoto Differences in in vivo and in vitro sequence-specific sites of cisplatin-DNA adduct formation and detection of a dose-response relationship Biochem. Pharmacol. 48 1994 145 153
18. A.M. Burger, J.A. Double, and D.R. Newell Inhibition of telomerase activity by cisplatin in human testicular cancer cells Eur. J. Cancer 33 1997 638 644
19. J.N. Burstyn, W.J. HeigerBernays, S.M. Cohen, and S.J. Lippard Formation of cis-diamminedichloroplatinum(II) 1,2-intrastrand cross-links on DNA is flanking-sequence independent Nucleic Acids Res. 28 2000 4237 4243
20. Z. Chen, and D.R. Corey Telomerase inhibitors: a new option for chemotherapy G.F. VandeWoude G. Klein Advances in Cancer Research vol. 87 2003 Academic Press Inc. San Diego/CA 31 58
21. P. Cheung, C.D. Allis, and P. Sassone-Corsi Signaling to chromatin through histone modifications Cell 103 2000 263 271
22. P.A. Clarke, K.E. Pestell, F. Di Stefano, P. Workman, and M.I. Walton Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo Br. J. Cancer 91 2004 1614 1623
23. S.M. Cohen, and S.J. Lippard Cisplatin: from DNA damage to cancer chemotherapy Prog. Nucleic Acid Res. Mol. Biol. 67 2001 93 130
24. M. Coluccia, F. Nassii, F. Loseto, A. Boccarelli, M.A. Marigió, and D. Giordano A trans-platinum complex showing higher antitumor activity than the cis congeners J. Med. Chem. 36 1993 510 512
25. R. Dalbies, M. Boudvillain, and M. Leng Linkage isomerization reaction of intrastrand cross-links in trans-diamminedichloroplatinum(II)-modified single-stranded oligonucleotides Nucleic Acids Res. 23 1995 949 953
26. R. Dalbies, D. Payet, and M. Leng DNA double helix promotes a linkage isomerization reaction in trans-diamminedichloroplatinum(II)-modified DNA Proc. Natl. Acad. Sci. U.S.A. 91 1994 8147 8151
27. B. Davidson, R. Reich, I. Goldberg, W.H. Gotlieb, J. Kopolovic, and A. Berner Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma Clin. Cancer Res. 7 2001 551 557
28. B. Desoize, and C. Madoulet Particular aspects of platinum compounds used at present in cancer treatment Crit. Rev. Oncol. Hematol. 42 2002 317 325
29. P.W. Doetsch, N.J. Morey, R.L. Swanson, and S. Jinks-Robertson Yeast base excision repair: interconnections and networks Prog. Nucleic Acid Res. Mol. Biol. 68 2001 29 39
30. J.T. Drummond, A. Anthoney, R. Brown, and P. Modrich Cisplatin and adriamycin resistance are associated with MutL alpha and mismatch repair deficiency in an ovarian tumor cell line J. Biol. Chem. 271 1996 19645 19648
31. L.H. Einhorn Inaugural article: curing metastatic testicular cancer Proc. Natl. Acad. Sci. U.S.A. 99 2002 4592 4595
32. N. Farrell Nonclassical platinum antitumor agents - perspectives for design and development of new drugs complementary to cisplatin Cancer Invest. 11 1993 578 589
33. N. Farrell Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry A. Sigel H. Sigel Metal Ions in Biological Systems vol. 32 1996 Marcel Dekker, Inc. New York/Basel/Hong Kong 603 639
34. N. Farrell Polynuclear charged platinum compounds as a new class of anticancer agents: toward a new paradigm L.R. Kelland N.P. Farrell Platinum-based Drugs in Cancer Therapy 2000 Humana Press Inc. Totowa/NJ 321 338
35. N. Farrell Polynuclear platinum drugs A. Sigel H. Sigel Metal Ions in Biological Systems vol. 42 2004 Marcel Dekker, Inc. New York, Basel 251 296
36. N. Farrell, L.F. Povirk, Y. Dange, G. DeMasters, M.S. Gupta, and G. Kohlhagenc Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells Biochem. Pharmacol. 68 2004 857 866
37. N. Farrell, Y. Qu, and M.P. Hacker Cytotoxicity and antitumor activity of bis(platinum) complexes - a novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes J. Med. Chem. 33 1990 2179 2184
38. C.G. Ferreira, C. Tolis, and G. Giaccone p53 and chemosensitivity Ann. Oncol. 10 1999 1011 1021
39. D. Fink, S. Nebel, S. Aebi, H. Zheng, B. Cenni, and A. Nehme The role of DNA mismatch repair in platinum drug resistance Cancer Res. 56 1996 4881 4886
40. D. Fink, H. Zheng, S. Nebel, P.S. Norris, S. Aebi, and T.P. Lin In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair Cancer Res. 57 1997 1841 1845
41. M. Foka, and J. Paoletti Interaction of cis-diamminedichloroplatinum(II) to chromatin. Specificity of the drug distribution Biochem. Pharmacol. 35 1986 3283 3291
42. L. Fourrier, P. Brooks, and J.M. Malinge Binding discrimination of MutS to a set of lesions and compound lesions (base damage and mismatch) reveals its potential role as a cisplatin-damaged DNA sensing protein J. Biol. Chem. 278 2003 21267 21275
43. M.A. Fuertes, J. Castilla, C. Alonso, and J.M. Perez Cisplatin biochemical mechanism of action: From cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways Curr. Med. Chem. 10 2003 257 266
44. M. Furuta, K. Nozawa, M. Takemura, S. Izuta, T. Murate, and M. Tsuchiya A novel platinum compound inhibits telomerase activity in vitro and reduces telomere length in a human hepatoma cell line Int. J. Cancer 104 2003 709 715
45. A.M. Galea, and V. Murray The interaction of cisplatin and analogues with DNA in reconstituted chromatin Biochim. Biophys. Acta 1579 2002 142 152
46. S. Ghosh, and M. Karin Missing pieces in the NF-kappa B puzzle Cell 109 2002 S81 S96
47. T.D. Gilmore NF-kappa-B, Kbf1, dorsal, and related matters Cell 62 1990 841 843
48. J.T. Hartmann, and H.P. Lipp Toxicity of platinum compounds Exp. Opin. Pharmacother. 4 2003 889 901
49. J. Hayes, and W.M. Scovell cis-Diamminedichloroplatinum(II) modified chromatin and nucleosomal core particle Biochim. Biophys. Acta 1089 1991 377 385
50. Q. He, C.H. Liang, and S.J. Lippard Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin Proc. Natl. Acad. Sci. U.S.A. 97 2000 5768 5772
51. M.S. Highley, and A.H. Calvert Clinical experience with cisplatin and carboplatin L.R. Kelland N.P. Farrell Platinum-based Drugs in Cancer Therapy 2000 Humana Press Inc. Totowa/NJ 171 194
52. R. Holmes, M. McKeage, V. Murray, W. Denny, and W. McFadyen cis-Dichloroplatinum(II) complexes tethered to 9-aminoacridine-4-carboxamides: synthesis and action in resistant cell lines in vitro J. Inorg. Biochem. 85 2001 209 217
53. E.R. Jamieson, and S.J. Lippard Structure, recognition, and processing of cisplatin-DNA adducts Chem. Rev. 99 1999 2467 2498
54. F. Janus, N. Albrechtsen, I. Dornreiter, L. Wiesmüller, F. Grosse, and W. Deppert The dual role model for p53 in maintaining genomic integrity Cell. Mol. Life Sci. 55 1999 12 27
55. N.P. Johnson, J.-L. Butour, G. Villani, F.L. Wimmer, M. Defais, and V. Pierson Metal antitumor compounds: the mechanism of action of platinum complexes Prog. Clin. Biochem. Med. 10 1989 1 24
56. S.W. Johnson, K.V. Ferry, and T.C. Hamilton Recent insights into platinum drug resistance in cancer Drug Resist. Update 1 1998 243 254
57. P. Jordan, and M. Carmo-Fonseca Molecular mechanisms involved in cisplatin cytotoxicity Cell. Mol. Life Sci. 57 2000 1229 1235
58. M. Kartalou, and J.M. Essigmann Recognition of cisplatin adducts by cellular proteins Mutat. Res. 478 2001 1 21
59. M. Kartalou, and J.M. Essigmann Mechanisms of resistance to cisplatin Mutat. Res. 478 2001 23 43
60. J. Kasparkova, M. Fojta, N. Farrell, and V. Brabec Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin Nucleic Acids Res. 32 2004 5546 5552
61. 3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts Biochemistry 42 2003 792 800
62. J. Kasparkova, S. Pospisilova, and V. Brabec Different recognition of DNA modified by antitumor cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53 J. Biol. Chem. 276 2001 16064 16069
63. J. Kasparkova, O. Vrana, N. Farrell, and V. Brabec Effect of the geometry of the central coordination sphere in antitumor trinuclear platinum complexes on DNA binding J. Inorg. Biochem. 98 2004 1560 1569
64. J. Kasparkova, J. Zehnulova, N. Farrell, and V. Brabec DNA interstrand cross-links of the novel antitumor trinuclear platinum complex BBR3464. Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair J. Biol. Chem. 277 2002 48076 48086
65. K. Kawanishi, Y. Miyagi, J. Yamamoto, Y. Miyagi, K. Nakamura, and J. Kodama Cytocidal effect and DNA damage of nedaplatin in vitro by simulating pharmacokinetic parameters Cancer Chemother. Pharmacol. 47 2001 303 308
66. Kerley-Hamilton, J.S., Pike, A.M., Li, N., DiRenzo, J., et al. A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embyronal carcinoma. Oncogene (in press).
67. H. Kostrhunova, and V. Brabec Conformational analysis of site-specific DNA cross-links of cisplatin-distamycin conjugates Biochemistry 39 2000 12639 12649
68. J. Kwon, K.B. Morshead, J.R. Guyon, R.E. Kingston, and M.A. Oettinger Mol. Cell 6 2000 1037 1048
69. L. Lan, T. Hayashi, R.M. Rabeya, S. Nakajima, S.-I. Kanno, and M. Takao Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells DNA Repair 3 2004 135 143
70. M. Leng, A. Schwartz, and M.J. Giraud-Panis Transplatin-modified oligonucleotides as potential antitumor drugs L.R. Kelland N.P. Farrell Platinum-based Drugs in Cancer Therapy 2000 Humana Press Inc. Totowa/NJ 63 85
71. F. Levi, G. Metzger, C. Massari, and G. Milano Oxaliplatin - pharmacokinetics and chronopharmacological aspects Clin. Pharmacokin. 38 2000 1 21
72. X.J. Lin, K. Ramamurthi, M. Mishima, A. Kondo, R.D. Christen, and S.B. Howell P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin Cancer Res. 61 2001 1508 1516
73. S.J. Lippard, and J.D. Hoeschele Binding of cis- dichlorodiammineplatinum(II) and trans-dichlorodiammineplatinum(II) to the nucleosome core Proc. Natl. Acad. Sci. U.S.A. 76 1979 6091 6095
74. J. Lokich What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin? Cancer Invest. 19 2001 756 760
75. H. Loskotova, and V. Brabec DNA interactions of cisplatin tethered to the DNA minor groove binder distamycin Eur. J. Biochem. 266 1999 392 402
76. S. Mabuchi, M. Ohmichi, Y. Nishio, T. Hayasaka, A. Kimura, and T. Ohta Inhibition of NF-kappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models J. Biol. Chem. 279 2004 23477 23485
77. S.C. Mann, P.A. Andrews, and S.B. Howell Short-term cis-diamminedichloro- platinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells Cancer Chemother. Pharmacol. 25 1990 236 240
78. K. Masutomi, and W.C. Hahn Telomerase and tumorigenesis Cancer Lett. 194 2003 163 172
79. H. Mese, Y. Ueyama, A. Suzuki, S. Nakayama, A. Sasaki, and H. Hamakawa Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line Chemotherapy 47 2001 136 142
80. M. Meyers, A. Hwang, M.W. Wagner, and D.A. Boothman Role of DNA mismatch repair in apoptotic responses to therapeutic agents Environ. Mol. Mutagen. 44 2004 249 264
81. J.T. Millard DNA modifying agents as tools for studying chromatin structure Biochimie 78 1996 803 816
82. J.T. Millard, and E.E. Wilkes cis- and trans-diamminedichloroplatinum(II) interstrand cross-linking of a defined sequence nucleosomal core particle Biochemistry 39 2000 16046 16055
83. Y.Q. Mo, Y.B. Gan, S.H. Song, J. Johnston, X.D. Xiao, and M.G. Wientjes Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach Cancer Res. 63 2003 579 585
84. N. Moeller, B.S. Kangarloo, I. Puscasu, C. Mock, B. Krebs, and J.E.A. Wolff Rational design of platinum chemotherapeutic drugs: hydrophobicity increases cytotoxicity Anticancer Res. 20 2000 4435 4439
85. 2)]: cross-linking between d(G) and complementary d(C) within oligonucleotide duplexes ChemBioChem 3 2002 61 67
86. P.J. Morin Drug resistance and the microenvironment: nature and nurture Drug Resist. Update 6 2003 169 172
87. G. Natile, and M. Coluccia Antitumor active trans-platinum compounds A. Sigel H. Sigel Metal Ions in Biological Systems vol. 42 2004 Marcel Dekker, Inc. New York/Basel 209 250
88. 2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and deficient cells exposed to cisplatin Cancer Res. 57 1997 3253 3257
89. A. Nehme, R. Baskaran, S. Nebel, D. Fink, S.B. Howell, and J.Y.J. Wang Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells Br. J. Cancer 79 1999 1104 1110
90. 2]. A concept for activation of the trans geometry in platinum antitumor complexes Nucleic Acids Res. 31 2003 6450 6460
91. A. O'Brate, and P. Giannakakou The importance of p53 location: nuclear or cytoplasmic zip code? Drug Resist. Update 6 2003 313 322
92. P.J. O'Dwyer, J.P. Stevenson, and S.W. Johnson Clinical pharmacokinetics and administration of established platinum drugs Drugs 59 2000 19 27
93. R.Z. Orlowski, and A.S. Baldwin NF-kappa B as a therapeutic target in cancer Trends Mol. Med. 8 2002 385 389
94. E. Papouli, P. Cejka, and J. Jiricny Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells Cancer Res. 64 2004 3391 3394
95. P. Perego, L. Gatti, C. Caserini, R. Supino, D. Colangelo, and R. Leone The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells J. Inorg. Biochem. 77 1999 59 64
96. 2(N,N-dimethylamine)(isopropylamine)] in A2780cisR ovarian tumor cells Metal-Based Drugs 8 2001 29 37
97. 2(dimethylamine) (isopropylamine)]: interstrand cross-link efficiency, DNA sequence specificity, and inhibition of the B-Z transition J. Med. Chem. 43 2000 2411 2418
98. K.E. Pestell, S.M. Hobbs, J.C. Titley, L.R. Kelland, and M.I. Walton Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line Mol. Pharmacol. 57 2000 503 511
99. A. Petitjean, and J.K. Barton Tuning the DNA reactivity of cis-platinum: conjugation to a mismatch-specific metallointercalator J. Am. Chem. Soc. 126 2004 14728 14729
100. J.W. Pierce, R. Schoenleber, G. Jesmok, J. Best, S.A. Moore, and T. Collins Novel inhibitors of cytokine-induced I-kappaB alpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo J. Biol. Chem. 272 1997 21096 21103
101. R. Prokop, J. Kasparkova, O. Novakova, V. Marini, A.M. Pizarro, and C. Navarro-Ranninger DNA interactions of new antitumor platinum complexes with trans geometry activated by a 2-metylbutylamine or sec-butylamine ligand Biochem. Pharmacol. 67 2004 1097 1109
102. R. Ravi, and A. Bedi NF-κB in cancer - a friend turned foe Drug Resist. Update 7 2004 53 67
103. J.T. Reardon, A. Vaisman, S.G. Chaney, and A. Sancar Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro- cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts Cancer Res. 59 1999 3968 3971
104. 4 telomeric sequence: a structural and cross-linking study Biochemistry 40 2001 8463 8470
105. + solutions Nucleic Acids Res. 31 2003 1605 1613
106. J. Reedijk Improved understanding in platinum antitumour chemistry Chem. Commun. 1996 801 806
107. J.D. Roberts, G. Beggiolin, C. Manzotti, L. Piazzoni, and N. Farrell Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines J. Inorg. Biochem. 77 1999 47 50
108. C.P. Rubbi, and J. Milner p53 is a chromatin accessibility factor for nucleotide excision repair of DNA damage EMBO J. 22 2003 975 986
109. M. Selvakumaran, D.A. Pisarcik, R. Bao, A.T. Yeung, and T.C. Hamilton Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines Cancer Res. 63 2003 1311 1316
110. Z.H. Siddik Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 2003 7265 7279
111. A. Slupianek, C. Schmutte, G. Tombline, M. Nieborowska-Skorska, G. Hoser, and M.O. Nowicki BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance Mol. Cell 8 2001 795 806
112. P.N. Span, P. Manders, J.J. Heuvel, C.M.G. Thomas, R.R. Bosch, and L.V. Beex Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer Oncogene 21 2002 8506 8509
113. D.C.J. Spierings, E.G. de Vries, E. Vellenga, and S. de Jong The attractive Achilles heel of germ cell tumours: an inherent sensitivity to apoptosis-inducing stimuli J. Pathol. 200 2003 137 148
114. B. Spingler, D.A. Whittington, and S.J. Lippard 2.4 Å crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex Inorg. Chem. 40 2001 5596 5602
115. G. Tallen, C. Mock, S.B. Gangopadhyay, B. Kangarloo, B. Krebs, and J.E.A. Wolff Overcoming cisplatin resistance: design of novel hydrophobic platinum compounds Anticancer Res. 20 2000 445 449
116. M.D. Temple, W.D. McFadyen, R.J. Holmes, W.A. Denny, and V. Murray Interaction of cisplatin and DNA-targeted 9-aminoacridine platinum complexes with DNA Biochemistry 39 2000 5593 5599
117. L.M. Thompson, and M.S.H. Arquilla The interaction of platinum complexes with nucleosomes investigated with fluorescent probes Biochim. Biophys. Acta 698 1982 173 182
118. T. Tomohiro, J. Sawada, C. Sawa, H. Nakura, S. Yoshida, and M. Kodaka Total analysis and purification of cellular proteins binding to cisplatin-damaged DNA using submicron beads Bioconj. Chem. 13 2002 163 166
119. A. Vaisman, S.E. Lim, S.M. Patrick, W.C. Copeland, D.C. Hinkle, and J.J. Turchi Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts Biochemistry 38 1999 11026 11039
120. A. Vaisman, M. Varchenko, A. Umar, T.A. Kunkel, J.I. Risinger, and J.C. Barrett The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts Cancer Res. 58 1998 3579 3585
121. N.I. Valkov, and D.M. Sullivan Tumor p53 status and response to topoisomerase II inhibitors Drug Resist. Update 6 2003 27 39
122. O. Vrana, V. Brabec, and V. Kleinwächter Polarographic studies on the conformation of some platinum complexes: relations to anti-tumour activity Anti-Cancer Drug Des. 1 1986 95 109
123. D. Wang, R. Hara, G. Singh, A. Sancar, and S.J. Lippard Nucleotide excision repair from site-specifically platinum-modified nucleosomes Biochemistry 42 2003 6747 6753
124. D. Wang, and S.J. Lippard Cisplatin-induced post-translational modification of histones H3 and H4 J. Biol. Chem. 279 2004 20622 20625
125. G. Wang, A. Dombkowski, L. Chuang, and X.X.S. Xu The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response Cell Res. 14 2004 303 314
126. G. Wang, L. Chuang, X. Zhang, S. Colton, A. Dombkowski, and J. Reiners The initiative role of XPC protein in cisplatin DNA damaging treatment-mediated cell cycle regulation Nucleic Acids Res. 32 2004 2231 2240
127. N. Wernert, F. Gilles, V. Fafeur, F. Bouali, M.B. Raes, and C. Pyke Stromal expression of C-Ets1 transcription factor correlates with tumor invasion Cancer Res. 54 1994 5683 5688
128. L.A. Wilson, H. Yamamoto, and G. Singh Role of the transcription factor Ets-1 in cisplatin resistance Mol. Cancer Ther. 3 2004 823 832
129. L.R. Wiseman, J.C. Adkins, G.L. Plosker, and K.L. Goa Oxaliplatin - a review of its use in the management of metastatic colorectal cancer Drugs Aging 14 1999 459 475
130. J.M. Woynarowski, S. Faivre, M.C.S. Herzig, B. Arnett, W.G. Chapman, and A.V. Trevino Oxaliplatin-induced damage of cellular DNA Mol. Pharmacol. 58 2000 920 927
131. J.M. Woynarowski, W.G. Chapman, C. Napier, M.C.S. Herzig, and P. Juniewicz Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA Mol. Pharmacol. 54 1998 770 777
132. F. Wu, X.J. Lin, T. Okuda, and S.B. Howell DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance Cancer Res. 64 2004 8029 8035
133. H.I. Wu, J.A. Brown, M.J. Dorie, L. Lazzeroni, and J.M. Brown Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin, and mitomycin C Cancer Res. 64 2004 3940 3948
134. X.M. Wu, W. Fan, S.W. Xu, and Y.K. Zhou Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group a antisense RNA in human lung adenocarcinoma cells Clin. Cancer Res. 9 2003 5874 5879
135. E.M. Yazlovitskaya, R.D. DeHaan, and D.L. Persons Prolonged wild-type p53 protein accumulation and cisplatin resistance Biochem. Biophys. Res. Commun. 283 2001 732 737
136. F. Yuan, L. Gu, S. Guo, C. Wang, and G.-M. Li Evidence for involvement of HMGB1 protein in human DNA mismatch repair J. Biol. Chem. 279 2004 20935 20940
137. D.B. Zamble, D. Mu, J.T. Reardon, A. Sancar, and S.J. Lippard Repair of cisplatin-DNA adducts by the mammalian excision nuclease Biochemistry 35 1996 10004 10013
138. D.B. Zamble, and S.J. Lippard The response of cellular proteins to cisplatin-damaged DNA B. Lippert Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug 1999 Wiley-VCH Zürich/Weinheim 73 110
139. Z.Z. Zdraveski, J.A. Mello, C.K. Farinelli, J.M. Essigmann, and M.G. Marinus MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA J. Biol. Chem. 277 2002 1255 1260
140. J. Zehnulova, J. Kasparkova, N. Farrell, and V. Brabec Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair of DNA intrastrand cross-links of novel antitumor trinuclear platinum complex BBR3464 J. Biol. Chem. 276 2001 22191 22199